{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:10:30Z","timestamp":1779077430078,"version":"3.51.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Prenatal cell-free DNA (cfDNA) screening is a success story of clinical genomics that has translated to and transformed obstetric care. It is a highly sensitive and specific method of screening for the most common fetal aneuploidies, including trisomies 13, 18, and 21. While primarily designed to detect fetal chromosomal abnormalities, the test also analyzes maternal cfDNA, which can complicate interpretation of results. Occasionally, abnormalities in cfDNA that do not align with fetal aneuploidy may indicate benign or malignant maternal disease states, presenting unique diagnostic challenges and opportunities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>This review explores the methods and implications of incidental cancer detection through prenatal cfDNA screening. Early case reports noted instances in which abnormal cfDNA results, initially suggestive of fetal aneuploidies, led to post-pregnancy diagnoses of maternal cancers. Subsequent large retrospective studies have established significant correlations between atypical prenatal cfDNA results and undiagnosed maternal malignancies. Abnormal cfDNA profiles, particularly those indicating multiple aneuploidies, first require fetal diagnostic tests, such as amniocentesis. If the fetal studies are normal, further investigation into a maternal source should proceed. Clinical management of these findings may involve a multidisciplinary approach, incorporating advanced imaging techniques and genetic counseling to ensure timely and accurate maternal diagnoses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The integration of genome-wide analysis and innovative bioinformatics tools into prenatal cfDNA screening has enhanced its ability to identify potential cancer cases. Developing standardized guidelines for reporting and managing incidental findings is crucial to optimizing patient outcomes and mitigating psychological impacts on expectant persons and their partners.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvae170","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:50:14Z","timestamp":1735897814000},"page":"61-68","source":"Crossref","is-referenced-by-count":4,"title":["Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies"],"prefix":"10.1093","volume":"71","author":[{"given":"Ian S","family":"Goldlust","sequence":"first","affiliation":[{"name":"Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5267","authenticated-orcid":false,"given":"Diana W","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Prenatal Genomics and Therapy Section, Center for Precision Health Research, National Human Genome Institute, National Institutes of Health , Bethesda, MD ,","place":["United States"]},{"name":"Office of the Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, MD ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"2025010523242311600_hvae170-B1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1056\/NEJMra1705345","article-title":"Sequencing of circulating cell-free DNA during pregnancy","volume":"379","author":"Bianchi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025010523242311600_hvae170-B2","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/AOG.0000000000004084","article-title":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for fetal chromosomal abnormalities: ACOG Practice Bulletin, number 226","volume":"136","author":"Rose","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2025010523242311600_hvae170-B3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/gim.2017.219","article-title":"Cherchez la femme: maternal incidental findings can explain discordant prenatal cell-free DNA sequencing results","volume":"20","author":"Bianchi","year":"2018","journal-title":"Genet Med"},{"key":"2025010523242311600_hvae170-B4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(97)02174-0","article-title":"Presence of fetal DNA in maternal plasma and serum","volume":"350","author":"Lo","year":"1997","journal-title":"Lancet"},{"key":"2025010523242311600_hvae170-B5","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1073\/pnas.0810641105","article-title":"Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma","volume":"105","author":"Chiu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025010523242311600_hvae170-B6","doi-asserted-by":"crossref","first-page":"16266","DOI":"10.1073\/pnas.0808319105","article-title":"Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood","volume":"105","author":"Fan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025010523242311600_hvae170-B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1311037","article-title":"DNA sequencing versus standard prenatal aneuploidy screening","volume":"370","author":"Bianchi","year":"2014","journal-title":"N Engl J Med"},{"key":"2025010523242311600_hvae170-B8","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa1407349","article-title":"Cell-free DNA analysis for noninvasive examination of trisomy","volume":"372","author":"Norton","year":"2015","journal-title":"N Engl J Med"},{"key":"2025010523242311600_hvae170-B9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-genom-083118-015053","article-title":"The emergence and global spread of noninvasive prenatal testing","volume":"22","author":"Ravitsky","year":"2021","journal-title":"Ann Rev Genomics Hum Genet"},{"key":"2025010523242311600_hvae170-B10","doi-asserted-by":"crossref","first-page":"e0167130","DOI":"10.1371\/journal.pone.0167130","article-title":"Improving the positive predictive value of non-invasive prenatal screening (NIPS)","volume":"12","author":"Strom","year":"2017","journal-title":"PLoS One"},{"key":"2025010523242311600_hvae170-B11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ajog.2023.11.1240","article-title":"Placental, maternal, fetal, and technical origins of false-positive cell-free DNA screening results","volume":"230","author":"Raymond","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"2025010523242311600_hvae170-B12","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1517\/14712598.2012.670632","article-title":"Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells","volume":"12","author":"Faas","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"2025010523242311600_hvae170-B13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajmg.c.31675","article-title":"Turner syndrome: new insights from prenatal genomics and transcriptomics","volume":"181","author":"Bianchi","year":"2019","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2025010523242311600_hvae170-B14","doi-asserted-by":"crossref","first-page":"e0146794","DOI":"10.1371\/journal.pone.0146794","article-title":"False negative NIPT results: risk figures for chromosomes 13, 18 and 21 based on chorionic villi results in 5967 cases and literature review","volume":"11","author":"Van Opstal","year":"2016","journal-title":"PLoS One"},{"key":"2025010523242311600_hvae170-B15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pd.4804","article-title":"The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon","volume":"36","author":"Yaron","year":"2016","journal-title":"Prenat Diagn"},{"key":"2025010523242311600_hvae170-B16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/AOG.0000000000002474","article-title":"Maternal malignancy evaluation after discordant cell-free DNA results","volume":"131","author":"Carlson","year":"2018","journal-title":"Obstet Gynecol"},{"key":"2025010523242311600_hvae170-B17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/PO.20.00429","article-title":"Cancer diagnoses following abnormal noninvasive prenatal testing: a case series, literature review, and proposed management model","volume":"5","author":"Dow","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025010523242311600_hvae170-B18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/OP.23.00594","article-title":"Comprehensive recommendations for the clinical management of pregnant women with noninvasive prenatal test results suspicious of a maternal malignancy","volume":"20","author":"Heesterbeek","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2025010523242311600_hvae170-B19","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.22.00733","article-title":"Prenatal DNA sequencing for fetal aneuploidy also detects maternal cancer: importance of timely workup and management in pregnant women","volume":"40","author":"Turriff","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025010523242311600_hvae170-B20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/pd.4973","article-title":"Prenatal cfDNA screening results indicative of maternal neoplasm: survey of current practice and management needs","volume":"37","author":"Giles","year":"2017","journal-title":"Prenat Diagn"},{"key":"2025010523242311600_hvae170-B21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pd.6406","article-title":"Patients\u2019 perspectives on prenatal screening results that suggest maternal cancer: a qualitative analysis","volume":"43","author":"Turriff","year":"2023","journal-title":"Prenat Diagn"},{"key":"2025010523242311600_hvae170-B22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/pd.5379","article-title":"Current controversies in prenatal diagnosis 2: NIPT results suggesting maternal cancer should always be disclosed","volume":"39","author":"Benn","year":"2019","journal-title":"Prenat Diagn"},{"key":"2025010523242311600_hvae170-B23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/pd.4100","article-title":"Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease","volume":"33","author":"Osborne","year":"2013","journal-title":"Prenat Diagn"},{"key":"2025010523242311600_hvae170-B24","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"key":"2025010523242311600_hvae170-B25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jamaoncol.2015.1883","article-title":"Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing","volume":"1","author":"Amant","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025010523242311600_hvae170-B26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jama.2015.7120","article-title":"Noninvasive prenatal testing and incidental detection of occult maternal malignancies","volume":"314","author":"Bianchi","year":"2015","journal-title":"JAMA"},{"key":"2025010523242311600_hvae170-B27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1373\/clinchem.2017.277517","article-title":"Incidental detection of maternal neoplasia in noninvasive prenatal testing","volume":"64","author":"Dharajiya","year":"2018","journal-title":"Clin Chem"},{"key":"2025010523242311600_hvae170-B28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41436-019-0510-5","article-title":"Identifying occult maternal malignancies from 1.93 million pregnant women undergoing noninvasive prenatal screening tests","volume":"21","author":"Ji","year":"2019","journal-title":"Genet Med"},{"key":"2025010523242311600_hvae170-B29","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ajhg.2019.10.005","article-title":"TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands","volume":"105","author":"van der Meij","year":"2019","journal-title":"Am J Hum Genet"},{"key":"2025010523242311600_hvae170-B30","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ajhg.2022.04.018","article-title":"Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: follow-up results of the TRIDENT-2 study","volume":"109","author":"van Prooyen Schuurman","year":"2022","journal-title":"Am J Hum Genet"},{"key":"2025010523242311600_hvae170-B31","doi-asserted-by":"crossref","first-page":"100856","DOI":"10.1016\/j.eclinm.2021.100856","article-title":"Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction. A single-center retrospective analysis of over 85,000 pregnancies","volume":"35","author":"Lenaerts","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025010523242311600_hvae170-B32","first-page":"791","article-title":"Maternal malignancy after atypical findings on single-nucleotide polymorphism-based prenatal cell-free DNA screening","volume":"141","author":"Goldring","year":"2023","journal-title":"Obstet Gynecol"},{"key":"2025010523242311600_hvae170-B33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/pd.6357","article-title":"Position statement from the International Society for Prenatal Diagnosis on the use of non-invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnancies","volume":"43","author":"Hui","year":"2023","journal-title":"Prenat Diagn"},{"key":"2025010523242311600_hvae170-B34","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.gim.2022.11.004","article-title":"Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Dungan","year":"2023","journal-title":"Genet Med"},{"key":"2025010523242311600_hvae170-B35","author":"California Department of Public Health"},{"key":"2025010523242311600_hvae170-B36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s00261-023-03913-1","article-title":"Noninvasive prenatal screening and maternal malignancy: role of imaging","volume":"48","author":"Jha","year":"2023","journal-title":"Abdom Radiol"},{"key":"2025010523242311600_hvae170-B37","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1508913","article-title":"Pediatric outcome after maternal cancer diagnosed during pregnancy","volume":"373","author":"Amant","year":"2015","journal-title":"N Engl J Med"},{"key":"2025010523242311600_hvae170-B38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/AOG.0000000000004873","article-title":"Pregnancy at age 35 years or older: ACOG obstetric care consensus no. 11","volume":"140","year":"2022","journal-title":"Obstet Gynecol"},{"key":"2025010523242311600_hvae170-B39","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025010523242311600_hvae170-B40","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood-2002-08-2577","article-title":"Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma","volume":"101","author":"Barth","year":"2003","journal-title":"Blood"},{"key":"2025010523242311600_hvae170-B41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41568-024-00719-1","article-title":"Oncologists must act to manage cancer detected through prenatal screening","volume":"24","author":"Turriff","year":"2024","journal-title":"Nat Rev Cancer"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/1\/61\/61283917\/hvae170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/71\/1\/61\/61283917\/hvae170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:24:49Z","timestamp":1736137489000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/71\/1\/61\/7933564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvae170","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}